Episode 339
Humans are finally going back to the moon. NASA’s Artemis II mission is set to launch in April, taking four astronauts in a loop around the moon. If it goes well, it’ll set the stage for a lunar landing by Artemis III - bringing us closer to creating permanent settlements on the surface. And that’s not all - SpaceX is planning to visit Mars this year as part of its plans to colonise the Red Planet. Plus, in May we might see the launch of a new American space station. Will these missions mark 2026 as the year that kick-started our spread off planet?
GLP-1 weight loss drugs are set to get cheaper this year. The patent on semaglutide - the active ingredient in drugs like Ozempic - is about to run out, meaning more people will be able to access these hugely impactful medications. A pill version is also on the horizon, plus one upcoming drug that can cut body weight by a whopping 24 per cent.
The first phase 3 trials of LSD are taking place this year. 55 years after being banned, the psychedelic drug is being tested once again for its ability to reduce anxiety and treat mental health conditions. Research suggests LSD can rewire your brain and relieve moderate to severe anxiety for at least three months. But will the trials prove its benefits outweigh any side effects?
A carbon border tariff is being imposed by the EU - taxing imports of materials like steel from countries that aren’t doing enough to keep their emissions down. The policy is a positive step for climate action and will help to make EU industries more competitive. And it looks like countries around the world are soon to follow suit.
Hosted by Rowan Hooper and Penny Sarchet, with guests Jacob Aron, Michael Le Page and Alexandra Thompson.
To read more about these stories, visit https://www.newscientist.com/
Learn more about your ad choices. Visit megaphone.fm/adchoices
